What is claimed is:

7 au sirmi

5luhraf A method of treatment of neurologic damage in a mammal, comprising the step of administering therapeutically effective amounts of thrombopoietin to the mammal.

- The method of claim 1 wherein the step of administering the thrombopoietin comprises orally ingesting the thrombopoietin.
- The method of claim 1 wherein the step of/administering the thrombopoietin comprises 3. intravenously injecting said thrombopoietin.
- 4. The method of claim 1 wherein the step of administering said thrombopoietin comprises intramuscularly injecting said thrombopoietin.
- 5. The method of claim 1 wherein the step of administering the thrombopoietin comprises intrathecally injecting the/thrombopoietin.
- The method of claim 1 further comprising the step of administering thyroid hormone to 20 6. the mammal.
 - 7. The method of claim 6 wherein said step of administering the thyroid hormone comprises orally ingesting the thyroid hormone.
 - 8. The method of claim 6 wherein said step of administering the thyroid hormone comprises intravenously injecting the thyroid hormone.

ootana .colyoo

□ 10

15

- The method of claim 6 wherein the step of administering said the roid hormone comprises 9. intramuscularly injecting the thyroid hormone.
- 10. The method of claim 6 wherein the step of administering/the thyroid hormone comprises intrathecally injecting the thyroid hormone.
 - The method of claim 6 wherein the step of administering the thyroid hormone comprises 11. administering thyroid hormone extract.
 - The method of claim 6 wherein the step of administering the thyroid hormone comprises 12. administering synthetic thyroid hormone.
 - 13. The method of claim 1 further including the step of stimulating human thyroid production by administering thyrotropin.
 - 14. The method of claim 13 wherein the step of administering the thyrotropin comprises orally ingesting the thyrotropin.
 - The method of claim 13 wherein the step of administering the thyrotropin comprises 15. intravenously injecting the thyrotropin.
 - The method of claim 13/wherein the step of administering the thyrotropin comprises 16. intramuscularly injecting the thyrotropin.
- 25 The method of claim 13 wherein the step of administering the thyrotropin comprises 17. intrathecally injecting the thyrotropin.

- 18. The method of claim 1 wherein the thrombopoietin is selected from the group consisting of a thrombopoietin isolated from a mammal, a thrombopoietin made by recombinant means, and a thrombopoietin made by synthetic means.
- The method of claim 1 wherein said thrombopoietin is selected from the group consisting of human thrombopoietin, a fragment of human thrombopoietin, and a variant polypeptide of human thrombopoietin.
 - 20. The method of claim 1 wherein the therapeutically effective amount ranges from about 1.0 to about 100 μg/kg body weight per day.
 - 21. The method of claim 6 wherein the thyroid hormone is co-administered to the mammal with the thrombopoietin.
 - 22. The method of claim 3 wherein the thyrotropin is co-administered to the mammal with the thrombopoietin.
 - 23. A pharmaceutical composition for treatment of neurologic damage in a mammal, comprising thrombopoietin and thyroid hormone.
 - 24. The composition of claim 23, comprising between about 0.07 to about 10 mg of thrombopoietin per dose unit.
- 25. The composition of claim 23 wherein the composition contains between about one and about three times the usual dose for thyroid hormone as for thrombopoietin.

5

- 26. The composition of claim 23 wherein the thrombopoietin is selected from the group consisting of a thrombopoietin isolated from a mammal, a thrombopoietin made by recombinant means, and a thrombopoietin made by synthetic means.
- 27. The composition of claim 23 wherein the thrombopoietin is selected from the group consisting of human thrombopoietin, a fragment of human thrombopoietin, and a variant polypeptide of human thrombopoietin.
- 28. The composition of claim 23 wherein the tryroid hormone is selected from the group consisting of thyroid hormone extract and synthetic thyroid hormone.
- 29. A pharmaceutical composition for treatment of neurologic damage in a mammal, comprising thrombopoietin and thyrotropin.
- 30. The composition of claim 29, comprising between about 0.07 to about 10 mg of thrombopoietin per dose unit.
- 31. The composition of claim 29 wherein the thrombopoietin is selected from the group consisting of a thrombopoietin isolated from a mammal, a thrombopoietin made by recombinant means, and a thrombopoietin made by synthetic means.
- 32. The composition of claim 29 wherein the thrombopoietin is selected from the group consisting of human thrombopoietin, a fragment of human thrombopoietin, and a variant polypeptide of human thrombopoietin.

